Ronald G Pearl, MD
Anesthesiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pearl’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G38269 · Current
Licensed to practise in California · since 1978 · expires 2028-10-31 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$45,686
Medicare paid this office $45,686 for 94 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 48 | $24,558 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,120 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,552 | $71 |
| Insertion of artery tube for blood sampling or infusion through skin | 17 | $639 | $38 |
Who their Medicare patients are
94 Original Medicare patients in 2024. Average age 73 · Women 45% · Also on Medicaid 35% · Health risk score 2.40. Sicker patients than 9 in 10 peers; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 75% · Atrial fibrillation 72% · Heart failure 71% · Coronary heart disease 69% · Chronic kidney disease 65% · Diabetes 53% · COPD 33% · Stroke 33% · Depression 32% · Cancer 23% · Dementia 23%.
The office billed $408,786, Medicare allowed $57,301 and paid $45,686; for 256 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 94 | 256 | 73 | 2.40 | $408,786 | $45,686 |
| 2023 | 111 | 338 | 71 | 2.84 | $506,970 | $57,737 |
| 2022 | 50 | 169 | 70 | 2.22 | $264,822 | $28,725 |
| 2021 | 51 | 153 | 75 | 2.96 | $223,063 | $25,758 |
| 2020 | 99 | 336 | 71 | 2.64 | $468,535 | $58,191 |
| 2019 | 150 | 475 | 72 | 2.11 | $655,797 | $74,346 |
| 2018 | 112 | 415 | 70 | 2.44 | $470,059 | $61,457 |
| 2017 | 132 | 470 | 72 | 1.86 | $614,719 | $73,000 |
| 2016 | 172 | 619 | 71 | 2.33 | $763,654 | $94,981 |
| 2015 | 163 | 546 | 71 | 2.39 | $661,052 | $79,094 |
| 2014 | 160 | 485 | 69 | 2.21 | $500,357 | $75,340 |
| 2013 | 130 | 376 | 72 | 2.10 | $382,802 | $57,503 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Critical care, first 30-74 minutes | 62 | $31,085 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,235 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,627 | $73 |
| Insertion of artery tube for blood sampling or infusion through skin | 20 | $781 | $39 |
2022: 2 services
| Critical care, first 30-74 minutes | 39 | $21,223 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,242 | $93 |
2021: 2 services
| Critical care, first 30-74 minutes | 31 | $18,138 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,100 | $95 |
2020: 2 services
| Critical care, first 30-74 minutes | 68 | $39,577 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,781 | $95 |
2019: 8 services
| Critical care, first 30-74 minutes | 95 | $41,010 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $7,358 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,706 | $66 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 17 | $1,824 | $76 |
| Insertion of artery tube for blood sampling or infusion through skin | 29 | $1,191 | $40 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,104 | $100 |
| Insertion of tube in pulmonary artery for monitoring | 13 | $1,024 | $79 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $32 | $3 |
2018: 6 services
| Critical care, first 30-74 minutes | 87 | $39,000 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $7,677 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,569 | $65 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 13 | $1,512 | $89 |
| Insertion of artery tube for blood sampling or infusion through skin | 11 | $426 | $39 |
| Ultrasonic guidance for blood vessel access | 11 | $154 | $13 |
2017: 9 services
| Critical care, first 30-74 minutes | 91 | $45,757 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $4,207 | $93 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 14 | $2,542 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $1,985 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,381 | $99 |
| Insertion of tube in pulmonary artery for monitoring | 11 | $1,231 | $112 |
| Insertion of artery tube for blood sampling or infusion through skin | 18 | $803 | $45 |
| Ultrasonic guidance for blood vessel access | 15 | $307 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $41 | $3 |
2016: 10 services
| Critical care, first 30-74 minutes | 127 | $58,421 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $4,907 | $93 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 21 | $3,930 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $3,215 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $2,069 | $109 |
| Insertion of tube in pulmonary artery for monitoring | 14 | $1,571 | $112 |
| Insertion of artery tube for blood sampling or infusion through skin | 24 | $1,071 | $45 |
| Ultrasonic guidance for blood vessel access | 14 | $320 | $13 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $119 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $55 | $3 |
2015: 7 services
| Critical care, first 30-74 minutes | 102 | $47,150 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $5,680 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $4,772 | $64 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 16 | $2,450 | $107 |
| Insertion of tube in pulmonary artery for monitoring | 12 | $1,345 | $112 |
| Insertion of artery tube for blood sampling or infusion through skin | 19 | $939 | $45 |
| Ultrasonic guidance for blood vessel access | 11 | $259 | $13 |
2014: 7 services
| Critical care, first 30-74 minutes | 85 | $38,800 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $4,621 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $3,715 | $64 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $3,202 | $107 |
| Insertion of artery tube for blood sampling or infusion through skin | 21 | $936 | $45 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $659 | $35 |
| Ultrasonic guidance for blood vessel access | 16 | $399 | $13 |
2013: 5 services
| Critical care, first 30-74 minutes | 78 | $28,624 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $6,122 | $62 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $2,706 | $104 |
| Insertion of artery tube for blood sampling or infusion through skin | 24 | $1,080 | $43 |
| Ultrasonic guidance for blood vessel access | 17 | $330 | $13 |
Medicaid work
$2,379 in 2021
Medicaid paid $2,379 for 26 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 26 | $2,379 |
| 2021 | 26 | 1 | 12 | $2,379 |
| 2020 | 73 | 1 | 14 | $6,687 |
| 2019 | 22 | 1 | 12 | $2,775 |
| 2018 | 19 | 1 | 12 | $1,585 |
See the largest Medicaid services in earlier years
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 73 | $6,687 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 22 | $2,775 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 19 | $1,585 |
Money from drug and device companies
$1,713 in 2025
| 2025 | 3 | 12 | None | $1,713 |
| 2024 | 2 | 2 | None | $139 |
| 2023 | 2 | 2 | None | $179 |
| 2022 | 1 | 1 | None | $167 |
| 2019 | 4 | 11 | $2,500 | $3,742 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alexion Pharmaceuticals | Ultomiris | $1,190 | 10 payments
|
| Novartis Pharmaceuticals | None | $401 | 1 payment
|
| Vertex Pharmaceuticals | Journavx | $122 | 1 payment
|
See all 12 published payments
| Vertex Pharmaceuticals | Meals · 2025-07-10 | Journavx | $122 |
| Alexion Pharmaceuticals | Travel · 2025-02-24 | Ultomiris | $35 |
| Alexion Pharmaceuticals | Meals · 2025-02-24 | Ultomiris | $22 |
| Alexion Pharmaceuticals | Travel · 2025-02-23 | Ultomiris | $169 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $27 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $36 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $15 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $27 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $50 |
| Alexion Pharmaceuticals | Meals · 2025-02-23 | Ultomiris | $108 |
| Novartis Pharmaceuticals | Travel · 2025-01-30 | None | $401 |
| Alexion Pharmaceuticals | Travel · 2025-01-14 | Ultomiris | $701 |
See earlier years (2024, 2023, 2022, 2019)
2024: $139
| Alexion Pharmaceuticals | None | $121 | 1 payment
|
| Merck Sharp & Dohme | Bridion | $18 | 1 payment
|
2023: $179
| Chiesi USA | Cleviprex | $121 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $58 | 1 payment
|
2022: $167
| Masimo | Sedline | $167 | 1 payment
|
2019: $3,742
| Portola Pharmaceuticals | Andexxa | $2,879 | 8 payments
|
| Cerus | Device-Transfusion | $653 | 1 payment
|
| AcelRx Pharmaceuticals | Dsuvia | $120 | 1 payment
|
| Avanos Medical | On-Q* Pump and Accessories | $89 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Cerus Corporation · Recepi · 2023 | Their institution | $168,518 |
| Cerus Corporation · Recepi · 2022 | Their institution | $139,649 |
| Cerus Corporation · Cli00125 Recepi · 2021 | Their institution | $120,684 |
| Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Dose-Finding Phase 2b Study To Investigate the Safety and Efficacy of Tin816 Via A Single Intravenous Infusion in the Treatment of Participants With Sepsis-Associated A · 2025 | Their institution | $83,426 |
| Genentech, Inc. · Study of the Efficacy and Safety of Gdc-8264 in Preventing Post-Cardiac Surgery Acute Kidney Injury · 2025 | Their institution | $51,350 |
| Cerus Corporation · Recepi · 2024 | Their institution | $49,375 |
| Cerus Corporation · Cli00125 - Recepi · 2020 | Their institution | $30,933 |
| Cerus Corporation · Cli00125 - Recepi · 2019 | Their institution | $24,156 |
| Alexion Pharmaceuticals, Inc. · Artemis Ravulizumab To Protect Patients With Chronic Kidney Disease (Ckd) From Cardiac Surgery Associated Acute Kidney Injury (Csa-Aki) and Subsequent Major Adverse Kidney Events (Make) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study · 2025 | Their institution | $22,171 |
| Janssen Research & Development, LLC · A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Subjects Hospitalized With Respiratory Syncytial Virus · 2019 | Their institution | $13,993 |
| Novartis Pharmaceuticals Corporation · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Dose-Finding Phase 2b Study To Investigate the Safety and Efficacy of Tin816 Via A Single Intravenous Infusion in the Treatment of Participants With Sepsis-Associated Acute Kidney Injury (Sa-Aki) · 2024 | Their institution | $1,737 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003958240
- Licence
- CA G38269California G38269: Current · expires 2028-10-31
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G382690
- Taxonomy
- Federal specialty code 207L00000X (207L00000X); Federal specialty code 207LC0200X (207LC0200X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-11
- NPI record certified
- 2024-04-11
This is when the NPI record was last certified, not a medical board exam.